Procter & Gamble Health, RateGain Travel Technologies, TTK Healthcare and Emcure Pharmaceuticals report strong quarterly earnings, suggesting resilient demand across healthcare and technology-linked sectors as the new financial year begins.
Four listed healthcare and technology-linked companies posted quarterly numbers just as the market session was ending, and the results pointed to a broadly healthy start to the new financial-year reporting cycle. Procter & Gamble Health, RateGain Travel Technologies, TTK Healthcare and Emcure Pharmaceuticals all reported year-on-year improvement in profit and revenue, with the strongest momentum coming from RateGain and Emcure, according to the company updates and market reports.
Procter & Gamble Health delivered a firmer quarter, with net profit rising to ₹96 crore from ₹66 crore a year earlier. Revenue increased to ₹364 crore from ₹339 crore, while earnings before interest, tax, depreciation and amortisation climbed to ₹100 crore from ₹90 crore. Margin also improved slightly to 27.3% from 26.6%, suggesting that cost control and operating efficiency continued to support performance. TTK Healthcare also advanced, lifting net profit to ₹21 crore from ₹13 crore and revenue to ₹258 crore from ₹226 crore.
The most striking gains came from RateGain and Emcure Pharmaceuticals. RateGain more than doubled net profit to ₹95 crore from ₹47 crore, while revenue surged to ₹785 crore from ₹273 crore. EBITDA rose to ₹171.5 crore from ₹50 crore and margin improved to 22% from 18.2%, underscoring a much stronger operating quarter. Emcure Pharmaceuticals, meanwhile, raised net profit to ₹294 crore from ₹207 crore and revenue to ₹2,580 crore from ₹2,100 crore. EBITDA increased to ₹532.5 crore from ₹417 crore and margin moved up to 20.6%.
Taken together, the figures suggest steady demand across the healthcare and allied businesses, with some companies also benefiting from tighter execution and better cost discipline. For investors, the day’s disclosures offered an encouraging early signal that the quarter may be producing broadly resilient earnings across select consumer health, pharma and travel-technology names.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
